A Clinical Study to Investigate Safety, Tolerability, and Preliminary Efficacy of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Adult Patients With Relapsed or Refractory B-NHL is a PHASE1 clinical asset sponsored by Ruijin Hospital in B-cell Non-Hodgkin Lymphoma. SEO and diligence focus: ABO2203 Injection, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.